Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 12, 2010, Pages 5443-5448

  Birzniece, Vita ^a,b   Sata, Akira ^a   Sutanto, Surya ^a   Ho, Ken K Y ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ARGININE; FOLLITROPIN; GENOX; GROWTH HORMONE; LUTEINIZING HORMONE; RALOXIFENE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG MECHANISM; GONAD; HUMAN; HUMAN EXPERIMENT; MALE; MEASUREMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 78650069151     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1477     Document Type: Article

References (27)

1. Meinhardt U, Nelson AE, Hansen JL, Birzniece V, Clifford D, Leung KC, Graham K, Ho KK 2010 The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized placebo-controlled trial. Ann Intern Med 152:568-577
2. Gibney J, Wolthers T, Johannsson G, Umpleby AM, Ho KK 2005 Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab 289:E266-E271
3. Weissberger AJ, Ho KK 1993 Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization. J Clin Endocrinol Metab 76:1407-1412
4. Veldhuis JD, Metzger DL, Martha Jr PM, Mauras N, Kerrigan JR, Keenan B, Rogol AD, Pincus SM 1997 Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal pathophysiology and sex-steroid hormone replacement. J Clin Endocrinol Metab 82:3414-3420
5. Veldhuis JD, Mielke KL, Cosma M, Soares-Welch C, Paulo R, Miles JM, Bowers CY 2009 Aromatase and 5α-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men. J Clin Endocrinol Metab 94:973-981
6. Rochira V, Zirilli L, Genazzani AD, Balestrieri A, Aranda C, Fabre B, Antunez P, Diazzi C, Carani C, Maffei L 2006 Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback. Eur J Endocrinol 155:513-522
7. Löfgren L, Wallberg B, Wilking N, Fornander T, Rutqvist LE, Carlström K, von Schoultz B, von Schoultz E 2004 Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids. Med Oncol 21:309-318
8. Riggs BL, Hartmann LC 2003 Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 348:618-629
9. Gooren LJ, van der Veen EA, van Kessel H, Harmsen-Louman W 1984 Estrogens in the feedback regulation of gonadotropin secretion in men: effects of administration of estrogen to agonadal subjects and the antiestrogen tamoxifen and the aromatase inhibitor delta'-testolactone to eugonadal subjects. Andrologia 16:568-577 (Pubitemid 15221153)
10. Stahl F, Schnorr D, Rohde W, Poppe I, Geier T, Dörner G 1983 Effects of tamoxifen on the levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin (PRL), 17 β-oestradiol (E2), total and free testosterone (T) and total and free dihydrotestosterone (DHT) in blood of patients with benign prostatic hyperplasia. Exp Clin Endocrinol 82:21-28 (Pubitemid 13020521)
11. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J 2008 Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197-213
12. Smith MR, Fallon MA, Lee H, Finkelstein JS 2004 Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841-3846
13. de Vos D, Slee PH, Stevenson D, Briggs RJ 1992 Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 31:76-78
14. Czock D, Keller F, Heringa M, Rasche FM 2005 Raloxifene pharmacokinetics in males with normal and impaired renal function. Br J Clin Pharmacol 59:479-482 (Pubitemid 40523893)
15. Fideleff HL, Frigeri AE, Sobrado PG, Llano MN, Ruibal GF, Boquete HR 1999 Reproducibility and variability of the arginine test in normal adults. Comparison between sexes. Medicina (B Aires) 59:249-253
16. Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK 2001 Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am J Physiol Endocrinol Metab 281:E1191-E1196 (Pubitemid 34001193)
17. Gibney J, Johannsson G, Leung KC, Ho KK 2005 Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women. J Clin Endocrinol Metab 90:3897-3903
18. Nguyen TV, Nelson AE, Howe CJ, Seibel MJ, Baxter RC, Handelsman DJ, Kazlauskas R, Ho KK 2008 Within-subject variability and analytic imprecision of insulin-like growth factor axis and collagen markers: implications for clinical diagnosis and doping tests. Clin Chem 54:1268-1276
19. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL 2003 The biological variation of testosterone and sex hormonebinding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 88:1528-1533
20. Birzniece V, Sata A, Sutanto S, Ho KK 2010 Paracrine regulation of growth hormone secretion by estrogen in women. J Clin Endocrinol Metab 95:3771-3776
21. Fodor M, Oudejans CB, Delemarre-van de Waal HA 2001 Absence of androgen receptor in the growth hormone releasing hormone-containing neurones in the rat mediobasal hypothalamus. J Neuroendocrinol 13:724-727
22. Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, Thorner MO 1998 Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 83:2836-2842
23. Corsello SM, Rota CA, Putignano P, Della Casa S, Barnabei A, Migneco MG, Vangeli V, Barini A, Mandalà M, Barone C, Barbarino A 1998 Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer. Eur J Endocrinol 139:309-313
24. Mandalà M, Moro C, Ferretti G, Calabro MG, Nolè F, Rocca A, Munzone E, Castro A, Curigliano G 2001 Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. Anticancer Res 21:585-588
25. Kelly JJ, Rajkovic IA, O'Sullivan AJ, Sernia C, Ho KK 1993 Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in postmenopausal women. Clin Endocrinol (Oxf) 39:561-567
26. Duschek EJ, Gooren LJ, Netelenbos C 2004 Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol 150:539-546
27. Duschek EJ, Gooren LJ, Netelenbos C 2005 Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. Maturitas 51:286-293